Staphylococcal peptidoglycan (PG) possesses in vivo immunodulating activity and is a B-cell mitogen in mice. The effect of PG on in vitro immune response of mouse splenocytes to sheep erythrocytes (SRBC) was studied, as well as the relationships between in vivo and in vitro adjuvant, immunosuppressive, and mitogenic activities of PG in terms of dose response, time kinetics, and physical state. Particulate PG suppressed in vivo anti-SRBC response when injected in a large dose before or simultaneously with SRBC. A small dose of particulate PG given before or along with the antigen was immunostimulatory. Soluble PG was adjuvant active in both high and low doses when injected before or along with the antigen. Both PG preparations were adjuvant active for mouse splenocytes in vitro immunized with SRBC, but particulate PG was more active. Even high doses of particulate PG were not directly suppressive for the in vitro immune response. Particulate PG was also mitogenic for mouse splenocytes, and the maximum increase in [3H]thymidine incorporation was observed after 2 days of culture. Soluble PG was not mitogenic during the 5-day incubation period. These results indicate that the physical state of PG, its dose, and its time of application are important factors determining its immunomodulating and mitogenic activities, and that by changing them it is possible to dissociate the adjuvant, immunosuppressive, and mitogenic properties of PG.
In vivo immunopotentiating activity of peptidoglycans (PG), basic cell wall heteropolymers of bacteria and actinomycetes, is a well-established phenomenon (11, 13, 15, 21) . Studies on the relationships between PG structure and activity associated its adjuvant properties with the soluble monomeric subunits composed of sugarpeptide complexes (1, 21 (23, 25) . This is also in agreement with the studies on the mechanism of adjuvant activity of MDP (8, 18, 24) . MDP is a synthetic analog of basic PG structure and, as mentioned above, it is adjuvant active while having no mitogenic effect on mouse lymphocytes. This opened the possi- The objective of this study was to evaluate the effect of PG on in vitro immune response and then to explore the relationships between in vivo and in vitro adjuvant and immunosuppressive activities of PG, as well as its mitogenic properties. These activities of PG were studied in terms of dose-response, time kinetics, and the physical state of the PG preparation. Two PG preparations were used: unsoluble, particulate PG naturally present in the cell wall, and soluble PG obtained by extensive ultrasonic disintegration. Striking differences in immunomodulating and mitogenic properties of these two preparations were observed.
MATERIALS AND METHODS
Mice. Female BALB/c mice, 6 to 8 weeks old, were obtained from Ace Animals, Inc., Boyertown, Pa., and fed a standard diet ad libitum.
PG. PG was isolated from Staphylococcus aurew 3528 cell walls by trichloroacetic acid extraction (7) and stored as an acetone-dried powder. Analysis of the chemical composition of PG revealed the presence of lysine, glutamic acid, glycine, alanine, glucosamine, and muramic acid (7), indicating no ificant contamination with teichoic acid, proteins, nucleic acids, or other cell components. Accidental contamination with exogenous endotoxins was ruled out by toxicity tests in adrenalectomized mice (6) . Before use, PG was suspended in sterile phosphate-buffered saline solution and treated with ultrasonication for 1 h at 20 kHz (8-W output) in a W/185 Sonifier (Branson Ultrasonics Co., Plainview, N.Y.), to yield a particulate PG preparation. To obtain a soluble preparation, PG was suspended in sterile distilled water and treated with ultrasonication as above. Supernatants were pooled after several 1-h ultrasonic disintegrations and centrifugations at 30,000 x g. Both PG preparations were heated at 700C for 1 h and tested for sterility.
In vivo iunomodulation experiments. Mice were immunized intravenously with 108 SRBC as previously described (5) . PG preparations were appropriately diluted in PBS and injected intravenously in 0.2-ml volumes. SRBC-specific plaque-forming cells (PFC) were assayed by the method of Cunningham and Szenberg (3) 4 days after SRBC challenge. The spleen ofeach mouse was assayed in triplicate cultures.
In vitro modulation experiments. In each experiment, spleen cells from at least three mice were pooled. In vitro cultures of dissociated spleen cells were established in 24-well tissue culture plates (Linbro Scientific, Inc., Hamden, Conn.) in Eagle basal medium with Hanks balanced salt solution supplemented with 10% fetal bovine serum, amino acids, and vitamins as described by Kamo et al. (14) . Spleen cells (2-ml cultures, 5 x 108 cells/ml) were immunized with 5 x 108 SRBC and incubated at 370C in a humid atmosphere containing 5% C02 and 95% air. PG preparations were appropriately diluted in the tissue culture medium and added (0.2 ml/well) at the initiation of the cultures. Cultures were always assayed individually for SRBC-specific PFC by the method of Jerne et al. (12) . Numbers of viable cells (excluding trypan blue dye) were also counted.
Significance of differences in PFC numbers in both in vivo and in vitro experiments was evaluated according to Student's t test, P c 0.05 being taken as a significant difference.
Mitogenicity studies. Mitogenicity was studied as previously described (6) (Fig. 1) ; the maximum effect was obtained with 200 ,Ag/ml. It was less active than particulate PG, but it did not decrease viability of the cells.
The influence of PG on the time kinetics of the in vitro immune response was also studied (Fig. 2, Table 2 ). Particulate PG caused an acceleration of the immune response during the first 3 days of culture and an overall increase in the response throughout the entire culture penod. On each of the days studied, the differences between treated and control cultures were statistically significant. Soluble PG caused an increase in the magnitude of the immune response during the first 4 days of culture, and on each of these days the differences between treated and control cultures were (Fig. 3) . Particulate PG caused a marked dose-dependent stimulation of mouse lymphocytes, with 400 jug/ml being the optimal mitogenic concentration, confirming our previous findings (6) . Soluble PG did not stimulate mouse spleen cells. Time kinetics studies were also performed to test whether the lack of mitogenic activity of soluble PG observed in the previous experiments was due to the early termination of the cultures. However, soluble PG was not stimulatory during 5-day culture period (Fig. 4) (Jug/ml) ulate PG given before or along with the antigen was immunostimulatory. Soluble PG was adjuvant active in both high and low doses when injected before or along with the antigen. Its in vivo immunostimulatory effect was greater than that obtained with low doses of particulate PG (Table 1) . Immunosuppression could not be induced by soluble PG with any doses or time regimens tested. It was recently shown, however, that multiple injections of high doses of MDP given before antigenic stimulation could suppress the anti-SRBC PFC response (16) .
In the in vitro immunization system, both PG preparations displayed a dose-dependent adjuvant activity. In this system, however, particulate PG was more active than soluble PG ( Fig.  1 and 2 ). Even high doses of particulate PG were not directly suppressive for the in vitro immune response when PG was added at the initiation of the cultures. Previous studies have shown, however, that the in vitro immune response of splenocytes from mice injected a day earlier with PG is suppressed to the same extent as the in vivo response (5a). This stresses the importance of time sequence in PG-induced immunosuppression; i.e., for the most effective suppression, PG must be injected before the antigenic stimulaINFECTr. IMMUN. tion. In the same study, it was also found that the suppressive effect is mediated by macrophages and the suppresion can be (at least to a certain extent) reproduced in vitro by treating macrophages with PG and then adding them to normal cell cultures.
The third important factor in PG-induced immunosuppression, as shown in this paper, is the physical state of PG. Only particulate PG was immunosuppressive; soluble PG was not. Both preparations were, however, adjuvant active, which indicates that different mechanisms are responsible for these two immunomodulatory events.
The adjuvant activity of PG could be dissociated from its mitogenic activity. As already discussed, both PG preparations were adjuvant active. Mitogenicity was associated only with particulate PG and was lost after its solubilization ( Fig. 3 and 4) . PG is a B-lymphocyte mitogen (6) . B-cell mitogenicity and polyclonal activation was suggested as the mechanism of adjuvant activity of a number of adjuvants (20) , including PG (4). From our studies, however, this seems not to be the case, at least for the adjuvant activity of PG. Soluble PG was adjuvant active but was not mitogenic, and even though particulate PG was both adjuvant active and mitogenic, the optimal concentration for its adjuvant effect was 25 ,ug/ml, whereas maximal mitogenic activity was obtained with 400 ug/ml ( Fig. 1 and  3) . Moreover, the adjuvant activity of PG was comparable when the results were calculated either per culture or per 106 viable cells, indicating that immunostimulatory effect did not depend on an increase in total cell number, but was due to increased numbers of SRBC-specific antibody-forming cells only.
Similar results were obtained with LPS, another potent B-cell mitogen and adjuvant. Studies on LPS-responder and -nonresponder mice indicated that adjuvanticity and mitogenicity represented distinct pathways of B-cell activation and were subject to different regulatory mechanisms (10) . It was also possible to chemically dissociate adjuvant from mitogenic activity of LPS (9) . A low-molecular-weight polysaccharide-rich preparation, extracted from Serratia marcescens LPS, stimulated the in vitro antibody response of mouse splenocytes and had no mitogenic activity.
However, some contribution of B-cell mitogenicity to the adjuvant effect of PG cannot be excluded, especially in the in vitro system, in which particulate PG exhibited higher activity than soluble PG. It appears from these studies that the overall effect of PG on the immune system is the result of interactions of different immunomodulating activities. The final outcome probably depends on a number of factors, including culture conditions, since it was recently reported that MDP had an adjuvant effect on in vitro immune response in low-density cultures (comparable to those described in this paper), whereas it was immunosuppressive for cells cultured at high densities (17) . Further studies are required to define more precisely the mechanisms of immunomodulating activities of PG and its derivatives.
